<DOC>
	<DOCNO>NCT00531960</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety Tarceva plus Avastin , chemotherapy plus Avastin , first-line treatment patient advance non-small cell lung cancer . Patients randomize receive either Tarceva 150mg p.o . daily plus Avastin 15mg/kg i.v . every 3 week , standard platinum-based chemotherapy ( 4-6 cycle ) plus Avastin . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Combination With Avastin ( Bevacizumab ) Patients With Advanced Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; advance ( stage IIIb IV ) nonsmall cell lung cancer ; measurable disease ; ECOG PS 01. prior chemotherapy treatment another systemic anticancer agent ; radiotherapy within 4 week prior first dose study treatment ; CNS metastases ; malignancy past 5 year , except adequately treated cancer situ cervix , basal squamous cell skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>